JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

CALCIFIED TISSUE INTERNATIONAL is a leading peer-reviewed journal published by Springer, dedicated to advancing our understanding of calcified tissues in relation to their physiological roles, pathophysiology, and therapeutic applications. With an impressive impact factor reflective of its importance in the field, this journal performs a crucial role in disseminating high-quality research that spans multiple disciplines, including Endocrinology, Orthopedics, and Sports Medicine. The journal is highly regarded within its respective categories, achieving Q1 rankings in Orthopedics and Sports Medicine, and demonstrating its commitment to excellence in scientific inquiry. While the journal operates under a traditional subscription model, it remains accessible to researchers and practitioners who seek to stay informed on the latest advancements and innovations in the study of calcified tissues. Established in 1973, CALCIFIED TISSUE INTERNATIONAL continues to be a vital resource for researchers, healthcare professionals, and students keen on exploring the intricate relationships between calcification processes and human health.

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

Translational Lung Cancer Research is a leading journal dedicated to advancing the field of oncology, particularly focusing on groundbreaking discoveries in lung cancer treatment and management. Published by AME Publishing Company, this journal boasts an impressive Q1 classification in the 2023 Oncology category, reflecting its significant contribution to the scientific community, with an outstanding Scopus rank of #92 out of 404 in Medicine _ Oncology, placing it in the 77th percentile. With its commitment to open access, the journal fosters international collaboration and accessibility, making cutting-edge research available to a wide audience. The scope of Translational Lung Cancer Research encompasses clinical trials, experimental studies, and translational research that bridge the gap between laboratory findings and clinical applications. Researchers, professionals, and students seeking to keep abreast of the latest developments in lung cancer research will find invaluable insights within its pages. For further information, please contact at FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

JOURNAL OF BONE AND MINERAL METABOLISM, published by SPRINGER JAPAN KK, is a leading peer-reviewed journal dedicated to advancing the field of bone and mineral research since its establishment in 1988. With ISSN 0914-8779 and E-ISSN 1435-5604, this esteemed journal offers a platform for high-quality research that intersects Endocrinology, Diabetes and Metabolism, Orthopedics and Sports Medicine, and related disciplines. Recognized for its rigorous standards, it holds a commendable Q2 ranking in multiple categories, reflecting its broad influence and relevance in contemporary medical research. Researchers and practitioners alike benefit from its evidence-based articles and insights, which contribute significantly to our understanding of metabolic bone diseases and mineral homeostasis. Although not an open-access journal, it still provides essential information and advancements crucial for professionals and scholars dedicated to improving clinical outcomes and enhancing patient care in these vital areas. To learn more, please explore the journal's archives and latest publications.

Bone Research is a premier open-access journal published by SpringerNature, dedicated to advancing the understanding of bone biology and its related disciplines. Established in 2013 and based in the United Kingdom, this journal has quickly ascended to the forefront of scientific inquiry, evidenced by its esteemed Q1 rankings in 2023 across multiple categories including Endocrinology, Diabetes and Metabolism, Histology, and Physiology. With a commendable impact reflected in its Scopus ranks—positioned #2 in Histology, #9 in Endocrinology, and #8 in Physiology—Bone Research serves as a vital platform for researchers, healthcare professionals, and students alike to share and access cutting-edge findings. Since adopting an open-access model in 2014, the journal has empowered an expansive audience by facilitating immediate availability of high-quality research. This aligns with its commitment to foster innovation and collaboration within the fields it encompasses. As it converges its efforts from 2013 to 2024, Bone Research remains a critical resource for those looking to deepen their investigation into bone health and diseases, ensuring its place as a leader in promoting scientific excellence.

The Journal of Cancer Research and Therapeutics is a prominent peer-reviewed platform dedicated to advancing scientific knowledge in the fields of oncology, radiology, and therapeutic interventions. Published by Wolters Kluwer Medknow Publications in India, this journal has been an essential resource for researchers and professionals since its inception in 2005, with a convergence of findings through to 2024. Although classified within the Q3 quartile across multiple relevant categories in the 2023 rankings, the journal maintains a significant impact in the fields of medicine, particularly in oncology and radiology, as evidenced by its Scopus rankings. The journal aims to disseminate high-quality research, case studies, and clinical trials that contribute to understanding and improving cancer treatments and patient care. With its accessibility to a global audience, the Journal of Cancer Research and Therapeutics plays a pivotal role in fostering dialogue and collaboration among researchers and healthcare professionals dedicated to combating cancer.

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.